BAJAJ BROKING

Notification
No new Notification messages
Virtual Galaxy Infotech IPO is Open!
Apply for the Virtual Galaxy Infotech IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

Cipla Warns of Margin Pressure in FY26–27 as Revlimid Phases Out

Synopsis:

Cipla has warned of margin pressure in FY26 and FY27 following the phase-out of Revlimid. Q4FY25 profit rose 30% to Rs.1,214 crore. Cipla share price remains flat as US sales declined and the company announces Rs.16 dividend per share.


Cipla has cautioned that margins in FY26 and FY27 may come under pressure due to the complete phase-out of generic Revlimid in the US market. While the March quarter results were ahead of analyst expectations in terms of net profit and revenue, concerns over future earnings dampened investor sentiment.

The company posted a 30% year-on-year jump in consolidated net profit to Rs.1,214 crore for Q4FY25, boosted by a 16% rise in other income and lower tax expenses. Revenue grew 9% year-on-year to Rs.6,729.69 crore, while EBITDA stood at Rs.1,537 crore, up 16.8% YoY.

Also read: Suven Life to Issue 6.4 Crore Convertible Warrants on Pref Basis

CIPLA LTD

Trade

1503.5-16.59 (-1.09 %)

Updated - 14 May 2025
1505.90day high
DAY HIGH
1474.60day low
DAY LOW
4042184
VOLUME (BSE)

Key Takeaways

  • Cipla net profit rose 30% YoY to Rs.1,214 crore in Q4FY25.

  • Revenue grew 9% YoY to Rs.6,729.69 crore.

  • US market sales fell from $226 million to $221 million.

  • Cipla declared a total dividend of Rs.16 per share for FY25.

  • Cipla share price dipped 0.4% to Rs.1,505.50 post results.

Also read: CCI Approves Indorama’s 24.9% Stake Acquisition in EPL Limited

US Sales Decline And Margin Outlook

Despite stronger profits, Cipla’s US sales fell to $221 million in Q4FY25, down 3% from the previous year. The phase-out of high-margin product Revlimid will weigh heavily on future performance, especially in FY26 and FY27.

EBITDA margins for Q4FY25 improved to 22.84%, up from 21% a year ago. However, with the exit of Revlimid from its portfolio, Cipla expects margin compression in the coming fiscal years, prompting a cautious outlook.

Cipla Q4FY25 Performance Snapshot

Metric

Q4FY25

Q4FY24

% Change YoY

Revenue (Rs. crore)

6,729.69

6,163

+9%

EBITDA (Rs. crore)

1,537

1,316

+16.8%

PAT (Rs. crore)

1,214

931

+30%

EBITDA Margin

22.84%

21%

+184 bps

US Sales (USD mn)

221

226

–3%

Dividend And Market Reaction

Cipla has announced a final dividend of Rs.13 per share and a special dividend of Rs.3 per share to mark its 90th anniversary, bringing the total to Rs.16 per share. The record date is set for June 27, 2025.

Following the results, Cipla share price dropped slightly by 0.4% to Rs.1,505.50 on Tuesday. The stock has declined by 2% year-to-date. With lower margins expected in the near term, Cipla share price may face further headwinds as investors reassess earnings visibility.

Also read: Chalet Hotels Aims for Double-Digit Revenue Growth in FY26

Share this article: 

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

10 lakh+ Users

icon-with-text

4+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4300+ Cr MTF Book

icon-with-text